 |
 |
 |
 |
 |
 |
 |
Oncology Trials
The Oncology Research Program, in partnership with local oncologists, offers patients access to leading-edge clinical trials sponsored by the National Cancer Institute's Cooperative Group Program or by pharmaceutical companies. These clinical trials study investigational drugs, new combinations of standard treatments for cancer, or cancer prevention in high risk patients.
For more information, please contact Suburban Hospital Oncology Research:
Barbara Squiller |
Melissa Hyman |
For information about clinical trials, visit the National Cancer Institute.
BREAST |
|
TAILORx |
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial |
MAP.3 |
A Phase III Randomized Study of Exemestane vs. Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer. |
05-C-02229 |
A Randomized Pilot Phase II Study of Docetaxel Alone or in Combination with PANVEC™-V (vaccinia) and PANVEC™-F (fowlpox) in Patients with Metastatic Breast Cancer |
IBCSG-24-02 |
A Phase III Randomized Study of Ovarian Function Suppression in Combination with Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women with Endocrine- Responsive Breast Cancer |
NSABP-B-36 |
A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC), With or Without Celecoxib, in Patients With Node- Negative Breast Cancer |
NSABP-B-39 |
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer |
CALGB 40101 |
Cyclophosphamide and Doxorubicin (CA) (4 VS 6 cycles) versus Paclitaxel (4 VS 6 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2 X 2 Factorial Phase III Randomized Study. |
MA17R |
A Phase III Randomized Double-Blind Study of Letrozole Versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen. |
NSABP B-42 |
A clinical trial to determine the efficacy of five years of Letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an Aromatase Inhibitor (AI) or Tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with Hormone Receptor Positive Breast Cancer. |
S0307 |
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer |
ECOG E5103 |
A double-blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High-risk Lymph Node Negative Breast Cancer. |
COLORECTAL |
|
E5202 |
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value Molecular Markers. |
NSABP R-04 |
A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine With Preoperative Radiation Therapy And Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in The Treatment of Patients with Operable Carcinoma of the Rectum |
GENITOURINARY |
|
S9346 |
Intermittant Androgen Deprivation with Stage D2 Prostate Cancer, Phase III |
E2805 |
A Randomized, Double-blind Phase III Trial of Adjuvant Sunitinib vs. Sorafenib vs. Placebo in Patients with Resected Renal Cell Carcinoma |
RTOG 0521 |
A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT, followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer. |